Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. (2017)
Attributed to:
Establishment of the Cambridge Single Cell Analysis Clinical Core Facility [SCACCF]
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.17863/cam.9805
Publication URI: https://www.repository.cam.ac.uk/handle/1810/264339
Type: Journal Article/Review